Bayer’s higher dose aflibercept 8 mg with extended treatment intervals is set for approval in the European Union (EU) for neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME).
Read More
FDA clears higher dose Eylea; approvals sought in other markets
The US FDA has approved the use of high dose Eylea (aflibercept) for three macular conditions, equating to longer intravitreal injection intervals for patients.
Read More
Read More
Opthea chooses non-proprietary drug name ‘sozinibercept’ for OPT-302
Clinical stage biopharmaceutical company Opthea, based in Melbourne, has adopted the non-proprietary drug name “sozinibercept” for its lead drug candidate, OPT-302.
Read More
Read More
Australian-made device by muPharma uses ultrasound to non-invasively deliver eye therapies
Melbourne biotech company muPharma, founded by ophthalmologist Dr Harry Unger and Mr Mark Unger, has developed an investigational device that uses ultrasound to deliver therapies non-invasively through ocular tissues, offering potential advantages over the standard of care for some retinal and corneal diseases.
Read More
Read More
Aflibercept 8mg could become AMD standard-of-care after pivotal trial
The drug company that produces Eylea (2 mg aflibercept) has announced clinical trial results showing the anti-VEGF therapy can be delivered at a higher doses at longer intervals, with a similar safety profile.
Read More
Read More